71.93 16.05 39.39 22.83 75.73 16.64 (50.65) (70.42) Note: The ratio in the income statement is presented as a percentage of total income. The cost of sales of real estate is shown as a percentage of
financial statement of the Company and its subsidiaries as at March 31, 2020 4 Note : 1 and 2 The company inform the Stock Exchange of Thailand on 22 April 2020. No. Contract No. Borrower Lender Appro ved
Remuneration Committee* 20,000 20,000 (Baht/Person/Meeting) Member of the Nomination and Remuneration Committee * 10,000 10,000 (Baht/Person/Meeting Note : * the meeting allowance shall be paid on a per-meeting
4,119,125 The total transaction from the period October 2020 to December 2020 is the amount of 4,119,125 Baht. Name, position and shareholding proportion of the connected persons. Note: 1Mr.Kazumasa Oshima is
profit margin 2.70% 46.22% (43.52%) DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 2 * Note the financial statements for the 3rd quarter ended
# -,.) @)ก ก #A B + NF/ ## *8##(E/ก# ## E +* (non P investment grade) 70/ / ## ++* 8ก# A**8##(E (Unrated) ?*,A0+ B + NF/ ## #N #, #7G (Structured Note) ก A0( # #N #, # (Derivatives) ?*, /E 0.(- ก
Case number 269/2563 (detailed in Note to the Financial Statements No.26) 4. Financial costs, amount Baht 4.80 million, decrease Baht 2.40 million or 33.26 percent because the Company has redeemed the
$ -,.) B)ก ก $C D + OH/ $$ *:$$(G/ก$ $$ G +* (non Q investment grade) 90/ / $$ ++* :ก$ C**:$$(G (Unrated) A*,C0+ D + OH/ $$ $O $, $9I (Structured Note) ก C0( $ $O $, $ (Derivatives) A*, /G 0.(- ก
$ -,.) @)ก ก $A B + NF/ $$ *9$$(E/ก$ $$ E +* (non P investment grade) 80/ / $$ ++* 9ก$ A**9$$(E (Unrated) ?*,A0+ B + NF/ $$ $N $, $8G (Structured Note) ก A0( $ $N $, $ (Derivatives) ?*, /E 0.(- ก